Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study
Prostate cancer (PC) and its treatment may affect PC survivors differently with respect to age. However, little is known regarding age-specific health-related quality of life (HRQoL) in PC survivors 5 years or even ≥ 10 years post-diagnosis.
The sample included 1975 disease-free PC survivors (5–16 years post-diagnosis) and 661 cancer-free population controls, recruited from two German population-based studies (CAESAR+, LinDe). HRQoL in both populations was assessed using the EORTC QLQ-C30 questionnaire. Additionally, PC survivors completed the PC-specific EORTC QLQ-PR25 questionnaire. Differences in HRQoL between survivors and controls, as well as differences according to age and time since diagnosis were analyzed with multiple regression after adjustment for age, education, stage, and time since diagnosis, where appropriate.
In general, PC survivors reported HRQoL and symptom-burden levels comparable to the general population, except for significantly poorer social functioning and higher burden for diarrhea and constipation. In age-specific analyses, PC survivors up to 69 years indicated poorer global health and social functioning than population controls. Stratification by time since diagnosis revealed little difference between the subgroups. On PC-specific symptoms, burden was highest for urinary bother and symptoms, and lowest for bowel symptoms. Younger age was associated with less urinary symptoms but higher urinary bother.
Long-term disease-free PC survivors reported overall good HRQoL, but experienced persistent specific detriments. Our data suggest that these detriments do not improve substantially with increasing time since diagnosis. Targeted interventions are recommended to prevent PC-related and treatment-related symptoms becoming chronic and to enhance social functioning.
KeywordsProstate cancer Health-related quality of life Long-term survivor Population-based
We thank all cancer survivors and doctors, who participated in the research.
The work of Salome Adam was supported by a fellowship grant of the Béatrice Ederer-Weber Stiftung. The CAESAR+ study was supported by a grant from the German Cancer Aid [No. 108262]. The LinDe study was supported by a grant from the German Cancer Aid [No. 110231]. The funding sources were neither involved in the collection, interpretation, and analysis of the data, nor in the decision for the writing and submission of this report for publication.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest. Authors declare that they have full control over all primary data and that the journal may review their data if required.
Ethical approvals for both studies were obtained from the internal review board (ethics committee) of the medical faculty of the University of Heidelberg and by all review boards accountable for the participating cancer registries. Written informed consent was obtained from all participants. All procedures involving human participants were in accordance with the Helsinki Declaration of 1975, as revised in 1983.
- 1.The Union for International Cancer Control’s. The Global Cancer Observatory - GLOBOCAN 2018 [Internet]. UICC.org. 2019 [cited 2019 Mar 18]. Available from: https://www.uicc.org/new-global-cancer-data-globocan-2018
- 2.National Coalition of Cancer Survivorship. The NCCS Definition of a “Cancer Survivor” [Internet]. [cited 2015 Jun 25]. Available from: http://www.canceradvocacy.org/news/defining-cancer-survivorship/
- 4.Robert Koch Institut. Zentrum für Krebsregisterdaten [Internet]. 2017 [cited 2018 Aug 29]. Available from: https://www.krebsdaten.de/Krebs/DE/Home/homepage_node.html
- 5.National Cancer Institute. Cancer trends progress report [Internet]. 2018 [cited 2018 Aug 29]. Available from: https://progressreport.cancer.gov/after/survival#field_most_recent_estimates
- 8.Adam S, Koch-Gallenkamp L, Bertram H, Eberle A, Holleczek B, Pritzkuleit R et al (2019) Health-related quality of life in long-term survivors with localised prostate cancer by therapy—results from a population-based study. Eur J Cancer Care (Engl). 28(5):e13076. https://doi.org/10.1111/ecc.13076
- 9.Namiki S, Kaiho Y, Mitsuzuka K, Saito H, Yamada S, Nakagawa H et al (2014) Long-term quality of life after radical prostatectomy: 8-year longitudinal study in Japan. Int J Urol Off J Japanese Urol Assoc. 21(12):1220–1226Google Scholar
- 11.van Stam MA, van der Poel HG, Bosch JLHR, Tillier CN, Horenblas S, Mols F et al (2017) Prevalence and correlates of mental health problems in prostate cancer survivors: a case-control study comparing survivors with general population peers. Urol Oncol Semin Orig Investig. 35(8):531.e1–531.e7CrossRefGoogle Scholar
- 14.Thong MSY, Mols F, Kil PJM, Korfage IJ, Van De Poll-Franse LV (2010) Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden. BJU Int. 105(5):652–658CrossRefGoogle Scholar
- 15.Clause-Verdreau AC, Audureau É, Leplège A, Coste J (2019) Contrasted trends in health-related quality of life across gender, age categories and work status in France, 1995-2016: repeated population-based cross-sectional surveys using the SF-36. J Epidemiol Community Health. 73(1):65–72CrossRefGoogle Scholar
- 16.Kurian CJ, Leader AE, Thong MSY, Keith SW, Zeigler-johnson CM (2018) Examining relationships between age at diagnosis and health-related quality of life outcomes in prostate cancer survivors. BMC Public Health. 18(1060):1–9Google Scholar
- 23.Koch-Gallenkamp L. Referenzdaten zur Lebensqualität in Deutschland für Studien mit Krebspatienten [Internet]. 2014. [cited 2018 Jun 5]. Available from: https://www.dkfz.de/de/klinepi/Projekte/linde-Studie.html
- 24.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85(5):365–376CrossRefGoogle Scholar
- 26.Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. Brussels Eur Organ Res Treat Cancer, Brussels, p 3Google Scholar
- 27.Cocks K, King MT, Velikova G, de Castro G, Martyn St-James M, Fayers PM et al (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 48(11):1713–1721CrossRefGoogle Scholar
- 29.Shin DW, Park HS, Lee SH, Jeon SH, Cho S, Kang SH et al (2018) Health-related quality of life, perceived social support, and depression in disease-free survivors who underwent curative surgery only for prostate, kidney and bladder cancer: comparison among survivors and with the general. Cancer Res TreatGoogle Scholar
- 33.De Vibe M, Bjørndal A, Hammerstrøm KT, Kowalski K, Tipton E (2017) Mindfulness based stress reduction (MBSR) for improving health, quality of life, and social functioning in adults. Campbell Syst Rev. 11(3)Google Scholar
- 34.Rothenberg BML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. Cancer. 19(18):3801–3807Google Scholar
- 37.Visser Mechteld R, Oort Frans J, van Lanschot Jan B, Van der Velden Jacobus, Kloek Jaap J, Gouma Dirk J, Schwartz Carolyn E, Sprangers MAG (2013) The role of recalibration response shift in explaining bodily pain in cancer patients undergoing invasive surgery: an empirical investigation of the Sprangersand Schwartz model. Psychooncology. 22(3):515–22CrossRefGoogle Scholar